Sino Biopharm (1177.HK) Declares 2025 Period in-between Outcomes

Pattern Highlights- Right thru the reporting duration, the Team had two modern products authorized for marketing and marketing by the NMPA, namely Putanning (Meloxicam Injection (II)) and Anqixin (Recombinant Human Coagulation Component VIIa N01 for Injection).- Within the first half of 2025, the Team’s sales of modern products reached RMB7.8 billion…
Be taught Extra